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Abstract
The dorsal raphe nucleus (DRN) is the origin of ascending serotonergic projections and is considered to be an important com-
ponent of the brain circuit that mediates anxiety- and depression-related behaviors. A large fraction of DRN serotonin-positive 
neurons contain nitric oxide (NO). Disruption of NO-mediated neurotransmission in the DRN by NO synthase inhibitors pro-
duces anxiolytic- and antidepressant-like effects in rats and also induces nonspecific interference with locomotor activity. We 
investigated the involvement of the 5-HT1A autoreceptor in the locomotor effects induced by NO in the DRN of male Wistar rats 
(280-310 g, N = 9-10 per group). The NO donor 3-morpholinosylnomine hydrochloride (SIN-1, 150, and 300 nmol) and the NO 
scavenger S-3-carboxy-4-hydroxyphenylglycine (carboxy-PTIO, 0.1-3.0 nmol) were injected into the DRN of rats immediately 
before they were exposed to the open field for 10 min. To evaluate the involvement of the 5-HT1A receptor and the N-methyl-D-
aspartate (NMDA) glutamate receptor in the locomotor effects of NO, animals were pretreated with the 5-HT1A receptor agonist 
8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT, 8 nmol), the 5-HT1A receptor antagonist N-(2-[4-(2-methoxyphenyl)-1-
piperazinyl]ethyl)-N-2-pyridinyl-cyclohexanecarboxamide maleate (WAY-100635, 0.37 nmol), and the NMDA receptor antagonist 
DL-2-amino-7-phosphonoheptanoic acid (AP7, 1 nmol), followed by microinjection of SIN-1 into the DRN. SIN-1 increased the 
distance traveled (mean ± SEM) in the open-field test (4431 ± 306.1 cm; F7,63 = 2.44, P = 0.028) and this effect was blocked 
by previous 8-OH-DPAT (2885 ± 490.4 cm) or AP7 (3335 ± 283.5 cm) administration (P < 0.05, Duncan test). These results 
indicate that 5-HT1A receptor activation and/or facilitation of glutamate neurotransmission can modulate the locomotor effects 
induced by NO in the DRN.
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Inhibition of the nitric oxide (NO) signaling pathway in the 
brain has been reported to induce anxiolytic- and antidepres-
sant-like effects in animal models. Systemic administration 
of the NO synthase (NOS) inhibitor N-methyl-L-arginine 
ester (L-NAME) (1,2) or the more selective neuronal NOS 
(nNOS) inhibitor 7-nitroindazole (2) produces anxiolytic-like 
effects in the elevated plus maze. The same compounds 
and the soluble guanylyl cyclase inhibitors methylene blue 
(3) dose-dependently reduce immobility time in the forced 
swimming test, a preclinical behavioral method for detecting 
antidepressant-like activity of drugs. 
The behavioral effects of NOS inhibitors appear to 
depend on endogenous serotonin (5-hydroxytryptamine, 
5-HT). Low doses of L-NAME that are ineffective at 3 mg/
kg potentiate the behavioral effects of imipramine and 
fluoxetine but not reboxetine, a norepinephrine reuptake 
inhibitor, in the forced swimming test (4). A functional 
interaction between 5-HT receptor subtypes and NO 
has been recently proposed. Ulak et al. (5) have shown 
that depletion of endogenous 5-HT or the antagonism of 
5-HT2 receptor prevented the antidepressant-like effect 
of 1-(2-trifluoromethylphenyl)-imidazole (TRIM), an nNOS 
inhibitor, implying that the antidepressant effects of TRIM 
might be mediated by an interaction with 5-HT2 receptors. 
5-HT2 receptors have been shown to mediate an increase 
in the hippocampal NOS activity induced by imipramine 
withdrawal in rats (6). Furthermore, hippocampal NOS is 
required for the functional activity of 5-HT1A receptors in 
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modulating anxiety-related behaviors (7). These findings 
suggest that nNOS may serve as a downstream signaling 
enzyme of the 5-HT neurotransmitter system (7). 
Nitric oxide has been involved in the release of several 
neurotransmitters. In the hippocampus and dorsal raphe 
nucleus (DRN), NO provides a tonic stimulus to maintain 
elevated levels of 5-HT release. Thus, nNOS inhibitors have 
been reported to cause an increase in hippocampal 5-HT 
efflux in the rat ventral hippocampus after local or systemic 
administration, whereas the NO precursor L-arginine had 
the opposite effect (8). These effects, however, may be 
region-dependent. When infused into the DRN, nNOS in-
hibitors decrease local extracellular 5-HT while increasing 
it in the frontal cortex (9).
The DRN is the origin of ascending serotonergic projec-
tions and is considered to be an important component of the 
brain circuit that mediates anxiety- and depression-related 
behaviors (10). 5-HT1A receptors are expressed presynapti-
cally in the DRN and act as inhibitory somatodendritic au-
toreceptors. A large fraction of DRN 5-HT-positive neurons 
also contain nNOS (11), suggesting that NO could interfere 
with DRN function. We recently showed that disruption of 
NO-mediated neurotransmission by the NOS inhibitors L-
NAME and 7-nitroindazole in the DRN produced anxiolytic- 
and antidepressant-like effects in rats (2). However, the 
effects occurred within a limited dose range, with low doses 
causing anxiolytic-like effects and high doses decreasing 
locomotor activity. These results suggest that NO-related 
drugs administered into the DRN may also induce the 
nonspecific interference of locomotor activity.
In the present study, we investigated the involvement 
of 5-HT1A receptors in the locomotor effects of NO admin-
istered into the DRN. Nitric oxide may increase glutamate 
release in the central nervous system, and 5-HT neurons in 
the DRN receive excitatory glutamatergic inputs from fore-
brain areas, hypothalamic nuclei and the lateral habenula 
(12). Therefore, we also tested the effects of pretreatment 
with DL-2-amino-7-phosphonoheptanoic acid (AP7), a 
glutamate N-methyl-D-aspartate (NMDA) receptor inhibitor, 
on the effects of NO in the DRN.
Material and Methods
Animals
Male Wistar rats (N = 127) weighing 280-310 g (77-91 
days) were transported to a colony room adjacent to the 
test laboratory 48 h before surgery. They were housed 5 per 
cage under a 12/12-h light/dark cycle (lights on at 7:00 am) 
at 23 ± 1°C and given free access to food and water. 
The experimental procedures used here were conducted 
in accordance with the Brazilian Society of Neuroscience 
and Behavior Guidelines for the Care and Use of Laboratory 
Animals, which comply with international guidelines and 
were approved by the Animal Ethics Committee of Univer-
sidade Estadual de Maringá, Paraná (CEEA/037/2007). All 
efforts were made to minimize animal suffering.
Experimental procedure
The animals were anesthetized with sodium pento-
barbital (45 mg/kg, ip) and fixed in a stereotaxic frame. A 
stainless steel guide cannula (outer diameter: 0.7 mm) was 
implanted in the DRN using to the following coordinates: 
anterior/posterior: ±1.4 mm from lambda, lateral: 3.7 mm, 
ventral: 6.2 mm (13). The guide cannula was inserted into 
the right hemisphere of the brain at a 36° angle to the verti-
cal plane to avoid the sagittal sinus. The tip of the guide 
cannula was positioned 1 mm above the DRN. After the 
surgical procedures, animals were housed 5 to a cage until 
behavioral testing.
Six to 7 days after surgery, the animals were transported 
to the test laboratory and were not disturbed for at least 1 h 
prior to testing. They were then randomly assigned to one 
of the treatment groups (N = 9-10/group).
For the microinjection procedure, a thin dental needle 
(outer diameter: 0.3 mm) was introduced through the guide 
cannula using a microsyringe (Hamilton, USA) controlled by 
an infusion pump (Kd Scientific, USA). A PE10 polyethylene 
catheter was interposed between the upper end of the dental 
needle and the microsyringe. The displacement of an air 
bubble inside the polyethylene tubing was used to monitor 
the microinjection process. The needle was held in place 
for an additional 1 min to maximize diffusion away from the 
injector tip. The animals received injections of saline or drugs 
into the DRN and were immediately placed in the center 
of an open-field apparatus (70 x 70 x 40 cm) for 10 min. 
Their behavior was videotaped and the distance traveled 
by them was determined by the Ethovision XT® software 
(Noldus Inc., Netherlands). For combined treatments, the 
animals received injections of saline or drugs, followed 
10 min later by saline or the NO donor 3-morpholinosyd-
nonimine (SIN-1). For all microinjections, including the 
first and second injections, the infused volume was 0.3 µL 
delivered over 30 s.
Drugs
The NO donor SIN-1 (150 and 300 nmol), the NO scav-
enger S-3-carboxy-4-hydroxyphenylglycine (carboxy-PTIO, 
0.1-3.0 nmol), the 5-HT1A agonist 8-hydroxy-2-(di-n-pro-
pylamino)tetralin (8-OH-DPAT, 8 nmol), the 5-HT1A receptor 
antagonist N-(2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl)-
N-2-pyridinyl-cyclohexanecarboxamide maleate (WAY-
100635, 0.37 nmol), and the glutamate NMDA receptor 
antagonist  AP7 (1 nmol) were dissolved in sterile isotonic 
saline. The drugs were purchased from Sigma Chemicals 
(USA). The solutions were prepared immediately before use. 
The doses of 8-OH-DPAT and WAY-100635 were chosen on 
the basis of studies showing no locomotor effects induced 
by these compounds when injected into the DRN (14,15). 
The doses of SIN-1 (2,16), carboxy-PTIO (17) and AP7 (16) 
were based on previous studies using direct administration 
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of these compounds into the dorsolateral periaqueductal 
gray matter (DLPAG). 
Histology
After behavioral analysis, the rats were sacrificed by 
deep urethane anesthesia and were perfused through the 
left ventricle of the heart with isotonic saline followed by a 
10% formalin. A dental needle was then inserted through 
the guide cannula, and 0.3 µL methylene blue was injected. 
The brains were removed and immersed in a 10% formalin 
for a minimum of 3 days. Coronal brain sections (50 µm) 
were then obtained with a cryostat (Cryocut 1800, Leica, 
Germany) and stained with cresyl violet. The injection sites 
were identified using diagrams from the atlas of Paxinos and 
Watson (13). Animals with injection sites located outside the 
DRN were excluded from the main statistical analysis but 
were combined in a group denoted “OUT” in Figure 1.
Statistical analysis
Data regarding the distance traveled by the rats were 
analyzed by one-way analysis of variance (ANOVA; Figure 
1). For combined treatments (Figure 2), data were analyzed 
by a two-way ANOVA, with the main factors being the first 
and second injections. In case of a significant interaction, 
the groups were compared by one-way ANOVA. Post-hoc 
comparisons were performed by the Duncan test. For 
ethical reasons, to minimize the number of animals used 
in this experiment, the same control (saline/saline) and 
SIN-1 (saline/SIN-1) groups were included in the experi-
ment presented in Figure 2. The level of significance was 
set at P < 0.05.
Results
Effects of SIN-1 and carboxy-PTIO on the distance 
traveled by rats in the open field
SIN-1, an NO donor, at 150 or 300 nmol significantly 
increased the distance traveled by the rats in the open field 
(F2,31 = 11.28, P = 0.002; Figure 1). No significant effect 
on distance traveled was detected after carboxy-PTIO 
administration into the DRN (F2,35 = 2.06; P = 0.13; Figure 
1). Animals that received SIN-1 or carboxy-PTIO outside 
the DRN (OUT) did not differ from controls (F6,70 = 3.51, 
P > 0.05; Figure 1). 
Pretreatment with 8-OH-DPAT or AP7 blocked the 
effects of SIN-1 on locomotor activity in rats
As expected, SIN-1 increased the distance traveled 
compared to all groups of the combined treatment (Figure 
2), except for the WAY-100635 + saline and WAY-100635 
+ SIN-1 groups (F7,63 = 2.47, P < 0.028; P < 0.05, Duncan 
test). ANOVA detected a significant interaction between 
the first and the second injection (F3,63 = 2.76, P = 0.049). 
The effects of SIN-1 were prevented by pretreatment with 
the selective 5-HT1A receptor agonist 8-OH-DPAT or the 
Figure 1. Effects of intra-DRN injection of the NO donor SIN-1 
(150 and 300 nmol) or carboxy-PTIO (0.1-3.0 nmol) on the dis-
tance traveled by rats in the open field for 10 min. The drugs were 
administered immediately before testing. Rats whose injections 
of SIN-1 or carboxy-PTIO were outside the DRN (N = 15) are 
reported in the OUT group. The height of the columns indicate 
the means, and the bars represent the SEM (N = 9-10/group). 
DRN = dorsal raphe nucleus; NO = nitric oxide; SIN-1 = 3-mor-
pholinosylnomine hydrochloride; carboxy-PTIO = S-3-carboxy-
4-hydroxyphenylglycine. *P < 0.05 compared to the saline (Sal) 
group (ANOVA followed by the Duncan test).
Figure 2. Effects of pretreatment with the 5-HT1A receptor ago-
nist 8-OH-DPAT (DPAT, 8 nmol), the 5-HT1A receptor antagonist 
WAY-100635 (WAY, 0.37 nmol) and the glutamate NMDA receptor 
antagonist AP7 (1 nmol) 10 min before SIN-1 (150 nmol) admin-
istration into the DRN in rats tested in the open field for 10 min. 
The height of the columns indicate the means, and the bars indi-
cate the SEM (N = 9-10/group). 8-OH-DPAT = 8-hydroxy-2-(di-n-
propylamino)tetralin; WAY-100635 = N-(2-[4-(2-methoxyphenyl)-
1-piperazinyl]ethyl)-N-2-pyridinyl-cyclohexanecarboxamide 
maleate; AP7 = DL-2-amino-7-phosphonoheptanoic acid; SIN-1 
= 3-morpholinosylnomine hydrochloride; DRN = dorsal raphe 
nucleus. *P < 0.05 compared to the saline + saline (Sal + Sal) 
group (ANOVA followed by the Duncan test); #P < 0.05 compared 
to the saline + SIN-1 (Sal + SIN-1) group (ANOVA followed by the 
Duncan test). 
NO and 5-HT1A in the dorsal raphe nucleus 335
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glutamate NMDA receptor antagonist AP7 before SIN-1 
administration (P < 0.05, Duncan test). These results sug-
gest that 5-HT1A receptors in the DRN may mediate the 
effects of NO on locomotor activity. The effects of SIN-1 
were also prevented by pretreatment with AP7 (P < 0.05, 
Duncan test). Since AP7 is a glutamate NMDA receptor 
antagonist, SIN-1 may also act by facilitating glutamate 
release in the DRN. No significant effect was detected with 
WAY-100635 pretreatment (P > 0.05, Duncan test). 
Discussion
Nonspecific suppression of rat locomotor activity by 
NO-related drugs has been reported previously. NOS inhibi-
tors, such as L-NAME (2) and methylene blue (3), reduce 
spontaneous locomotor activity in a dose-dependent way 
and may induce catalepsy in rodents (18). The latter effect 
involves NOS inhibition in the striatum. However, other brain 
areas have been shown to be involved in the systemic ef-
fects of NOS inhibitors on locomotor activity. Spiacci Jr. et 
al. (2) showed that NOS inhibitors injected into the DRN 
decreased, whereas the cyclic guanosine monophosphate 
(cGMP) analog 8-Br-cGMP dose-dependently increased, 
locomotor activity in rats, implicating NO neurotransmission 
in the DRN in the modulation of locomotor behavior. 
In the present study, administration of SIN-1, an NO 
donor, into the DRN increased the distance traveled by 
rats in the open field. Pretreatment with the 5-HT1A recep-
tor agonist 8-OH-DPAT or the NMDA receptor antagonist 
AP7 blocked the effects of SIN-1 on the locomotor activity 
of rats. Although a slight increase in locomotor activity was 
detected with WAY-100635 administration into the DRN, 
this effect was not statistically significant and did not modify 
the effects of SIN-1.
The activity of DRN neurons is under complex regulatory 
control mediated by the medial prefrontal cortex and lateral 
habenula, a process that involves excitatory glutamate 
inputs to serotonergic and γ-aminobutyric acid (GABA) 
neurons (19). The glutamatergic inputs are mediated, at 
least in part, by NMDA receptors, resulting in NO formation. 
Nitric oxide thus modulates the local release of glutamate, 
GABA, and 5-HT, having complex effects on DRN neuronal 
activity and implying interference of motor and emotion-
related processes. The DRN innervates emotion-related 
areas such as the amygdala, hippocampus and DLPAG (19). 
It also sends 5-HT fibers to the striatum, a motor-related 
area where they can modulate motor function. 
We showed that NO neurotransmission in the DRN 
mediates anxiolytic- and antidepressant-like effects in rats, 
which were followed by significant locomotor changes (2). 
The fact that the locomotor effects of SIN-1 were prevented 
by AP7, a glutamate NMDA receptor antagonist, suggests 
that SIN-1 may act by facilitating glutamate release in the 
DRN. Similar mechanisms have been implicated in the 
escape responses produced by SIN-1 administration into 
the DLPAG. In this region, escape responses appear to be 
modulated also by 5-HT because these effects were inhib-
ited by the 5-HT2A/2C receptor agonist 1-(2,5-dimethoxy-4-
iodophenyl)-2-aminopropane (DOI) (20). 
The present study demonstrated that the increased 
locomotor activity induced by SIN-1 administration into 
the DRN was prevented by pretreatment with the 5-HT1A 
receptor agonist 8-OH-DPAT. Considering this evidence, 
it is possible that 5-HT1A receptors in the DRN mediate 
the effects of NO on locomotor activity. Recently, it was 
demonstrated that administration of the 5-HT1A receptor 
agonist 8-OH-DPAT into the DRN favored the expression 
of the escape, which was chemically induced by SIN-1 ad-
ministration into the DLPAG while intra-DRN injection of the 
WAY-100635 did not change this defensive behavior (14). 
These findings support the view that DRN 5-HT1A autorecep-
tors are under the tonic inhibitory influence of 5-HT. In this 
respect, an interesting interaction between NO and 5-HT 
has been demonstrated in the regulation of anxiety- and 
depressive-related behaviors. Zhang et al. (7) have shown 
that nNOS is required not only for the anxiolytic-like effects 
of the 5-HT1A receptor agonist 8-OH-DPAT but also for the 
anxiogenic-like effects of the 5-HT1A receptor antagonist 
1-(methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine 
(NAN-190), indicating that NO may serve as a downstream 
signaling enzyme of 5-HT1A receptor functions. 
Contrary to expectations, however, administration of 
carboxy-PTIO failed to change the locomotor activity when 
injected into the DRN. It is possible that exogenous NO, 
delivered by SIN-1 was more effective in interfering with 
locomotion than the effect of the NO scavenger, carboxy-
PTIO. The results of our study also revealed that pretreat-
ment of rats with WAY-100635 did not affect locomotor 
activity or increase the effects of SIN-1. WAY-100635 slightly 
increased the distance traveled in the open field, but this 
effect was not statistically significant. The failure of WAY-
100635 to modify the increased locomotor activity produced 
by SIN-1, however, is consistent with reports showing that 
WAY-100635 injected into the DRN at the same dose (0.37 
nmol) presented a panicolytic-like effect without affecting 
locomotion (12) and did not change defensive behaviors 
induced by DLPAG stimulation (14). To better clarify the 
interaction between NO and 5-HT1A receptors in the DRN, 
however, further experiments need to be conducted.
The present results indicate that exogenous NO ad-
ministration into the DRN increases locomotor activity in 
rats, and this effect is mediated at least in part by 5-HT1A 
receptor activation and/or facilitation of glutamate NMDA 
receptor-mediated neurotransmission in this region.
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